Bioprinting of a Blue Light-Cross-Linked Biodegradable Hydrogel Encapsulating Amniotic Mesenchymal Stem Cells for Intrauterine Adhesion Prevention

AbstractCancer is a leading cause of death in both developed and developing countries, and because of population growth and aging, it is a growing medical burden worldwide. With robust development in medicine, the use of stem cells has opened new treatment modalities in cancer therapy. In adult stem cells, mesenchymal stem cells (MSCs) are showing rising promise in cancer treatment due to their unique properties. Among different sources of MSCs, human amniotic fluid/membrane is an attractive and suitable reservoir. There are conflicting opinions about the role of human amniotic membrane/fluid mesenchymal stem cells (hAMSCS/hAFMSCs) in cancer, as some studies demonstrating the anticancer effects of these cells and others suggesting their progressive effects on cancer. This review focuses on recent findings about the role of hAMSCs/hAFMSCs in cancer treatment and summarizes the suppressing as well as promoting effects of these cells on cancer progression and underling mechanisms.

Download Full-text

Intravenous Administration of Human Amniotic Mesenchymal Stem Cells in the Subacute Phase of Cerebral Infarction in a Mouse Model Ameliorates Neurological Disturbance by Suppressing Blood Brain Barrier Disruption and Apoptosis via Immunomodulation

Cell Transplantation ◽

10.1177/09636897211024183 ◽

2021 ◽

Vol 30 ◽

pp. 096368972110241

Author(s):

Yasunori Yoshida ◽

Toshinori Takagi ◽

Yoji Kuramoto ◽

Kotaro Tatebayashi ◽

Manabu Shirakawa ◽

...

Keyword(s):

Stem Cells ◽

Mesenchymal Stem Cells ◽

Mouse Model ◽

Cerebral Infarction ◽

Blood Brain Barrier ◽

Brain Infarction ◽

Brain Barrier ◽

Neurological Deficits ◽

Immunomodulatory Effects ◽

Amniotic Mesenchymal Stem Cells

Neuro-inflammation plays a key role in the pathophysiology of brain infarction. Cell therapy offers a novel therapeutic option due to its effect on immunomodulatory effects. Amniotic stem cells, in particular, show promise owing to their low immunogenicity, tumorigenicity, and easy availability from amniotic membranes discarded following birth. We have successfully isolated and expanded human amniotic mesenchymal stem cells (hAMSCs). Herein, we evaluated the therapeutic effect of hAMSCs on neurological deficits after brain infarction as well as their immunomodulatory effects in a mouse model in order to understand their mechanisms of action. One day after permanent occlusion of the middle cerebral artery (MCAO), hAMSCs were intravenously administered. RT-qPCR for TNFα, iNOS, MMP2, and MMP9, immunofluorescence staining for iNOS and CD11b/c, and a TUNEL assay were performed 8 days following MCAO. An Evans Blue assay and behavioral tests were performed 2 days and several months following MCAO, respectively. The results suggest that the neurological deficits caused by cerebral infarction are improved in dose-dependent manner by the administration of hAMSCs. The mechanism appears to be through a reduction in disruption of the blood brain barrier and apoptosis in the peri-infarct region through the suppression of pro-inflammatory cytokines and the M2-to-M1 phenotype shift.

Download Full-text

miR-138/miR-222 Overexpression Characterizes the miRNome of Amniotic Mesenchymal Stem Cells in Obesity

Stem Cells and Development ◽

10.1089/scd.2016.0127 ◽

2017 ◽

Vol 26 (1) ◽

pp. 4-14 ◽

Cited By ~ 9

Author(s):

Carmela Nardelli ◽

Ilaria Granata ◽

Laura Iaffaldano ◽

Valeria D'Argenio ◽

Valentina Del Monaco ◽

...

Keyword(s):

Stem Cells ◽

Mesenchymal Stem Cells ◽

Amniotic Mesenchymal Stem Cells

Download Full-text

Osteogenic differentiation of human amniotic mesenchymal stem cells in chitosan-carbonate apatite scaffold (in vivo study)

Contemporary Clinical Dentistry ◽

10.4103/ccd.ccd_627_18 ◽

2018 ◽

Vol 9 (4) ◽

pp. 592

Author(s):

MichaelJosef Kridanto Kamadjaja ◽

Sherman Salim ◽

FedikAbdul Rantam ◽

Ni PutuMira Sumarta

Keyword(s):

Stem Cells ◽

Mesenchymal Stem Cells ◽

Osteogenic Differentiation ◽

In Vivo Study ◽

Carbonate Apatite ◽

Amniotic Mesenchymal Stem Cells

Download Full-text

Effects of Interferon-γ on Proliferation and Ability of Secretion of Human Amniotic Mesenchymal Stem Cells

Blood ◽

10.1182/blood-2019-125500 ◽

2019 ◽

Vol 134 (Supplement_1) ◽

pp. 5012-5012

Author(s):

Ya Gao ◽

Ying Xu ◽

Weiru Li ◽

Yintian Zhang ◽

Baohong Ping ◽

...

Keyword(s):

Stem Cells ◽

Mesenchymal Stem Cells ◽

Conflicts Of Interest ◽

Interferon Γ ◽

Cell Counting ◽

Inflammatory Factors ◽

Complete Medium ◽

Amniotic Mesenchymal Stem Cells ◽

Soluble Hla ◽

Ifn Γ

Objective:The immunoregulatory properties and proliferation of mesenchymal stem cells (MSCs) could be affected by inflammatory factors. However, there have been few studies about human amniotic MSCs (hAMSCs). We investigated the effects of interferon (IFN)-γ on the proliferation and apoptosis of hAMSCs, and measured the level of inflammatory factors secreted by hAMSCs. Result:hAMSCs were cultured with complete medium with different concentrations of IFN-γ. We detected the proliferation of hAMSCs by Cell Counting Kit-8 assays, analysed apoptosis by flow cytometry (FCM) at 48 h, and mesasured the level of inflammatory factors such as solube HLA-G and prostaglandin E2 (PGE2) in the supernatant at 48 h by ELISA. The level of kynurenine (KYN) was measured by ultraviolet spectrophotometry. As culture time increased, the proliferation of hAMSCs with different concentrations of IFN-γ increased rapidly from day 1 to day 4, and then the growth rate slowed. FCM indicated that there was no significant apoptosis in the 100 ng/ml IFN-γ group compared with cells without IFN-γ. The level of PGE2 and soluble HLA-G in cells with IFN-γ was higher compared with those without IFN-γ. The level of KYN increased significantly in the cells with IFN-γ. Conclusion:IFN-γ did not affect the growth and proliferation of hAMSCs, and promoted secretion of PGE2 and soluble HLA-G, and enhanced activity of indoleamine 2,3-dioxygenase (IDO), providing a theoretical basis for hAMSCs to prevent and treat graft-versus-host disease. Disclosures No relevant conflicts of interest to declare.

Download Full-text

The Latest Developments in Immunomodulation of Mesenchymal Stem Cells in the Treatment of Intrauterine Adhesions, Both Allogeneic and Autologous

Frontiers in Immunology ◽

10.3389/fimmu.2021.785717 ◽

2021 ◽

Vol 12 ◽

Author(s):

Jia-ming Chen ◽

Qiao-yi Huang ◽

Yun-xia Zhao ◽

Wei-hong Chen ◽

Shu Lin ◽

...

Keyword(s):

Stem Cells ◽

Mesenchymal Stem Cells ◽

Mhc Class I ◽

Mhc Class Ii ◽

The Body ◽

Immune Rejection ◽

Intrauterine Adhesions ◽

Allogeneic Mscs ◽

Intrauterine Adhesion ◽

Low Levels

Intrauterine adhesion (IUA) is an endometrial fibrosis disease caused by repeated operations of the uterus and is a common cause of female infertility. In recent years, treatment using mesenchymal stem cells (MSCs) has been proposed by many researchers and is now widely used in clinics because of the low immunogenicity of MSCs. It is believed that allogeneic MSCs can be used to treat IUA because MSCs express only low levels of MHC class I molecules and no MHC class II or co-stimulatory molecules. However, many scholars still believe that the use of allogeneic MSCs to treat IUA may lead to immune rejection. Compared with allogeneic MSCs, autologous MSCs are safer, more ethical, and can better adapt to the body. Here, we review recently published articles on the immunomodulation of allogeneic and autologous MSCs in IUA therapy, with the aim of proving that the use of autologous MSCs can reduce the possibility of immune rejection in the treatment of IUAs.

Download Full-text